Repligen (NASDAQ:RGEN) Reaches New 12-Month Low – Here’s What Happened

Repligen Corporation (NASDAQ:RGEN) hit a new 52-week low during trading on Friday . The stock traded as low as $109.50 and last traded at $114.06, with a volume of 2174671 shares trading hands. The stock had previously closed at $124.40.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on RGEN shares. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, March 3rd. Wells Fargo & Company lowered their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Roth Mkm began coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price target on the stock. Finally, Barclays reduced their price objective on Repligen from $175.00 to $145.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.93.

Repligen Trading Down 8.3%

The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average is $123.53 and its 200 day moving average is $145.82. The company has a market cap of $6.43 billion, a price-to-earnings ratio of 134.19, a price-to-earnings-growth ratio of 2.42 and a beta of 1.19.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. During the same quarter in the prior year, the firm posted $0.44 earnings per share. The company’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Research analysts predict that Repligen Corporation will post 1.97 EPS for the current year.

Hedge Funds Weigh In On Repligen

A number of large investors have recently bought and sold shares of RGEN. Pictet Asset Management Holding SA boosted its position in Repligen by 12.0% during the first quarter. Pictet Asset Management Holding SA now owns 8,449 shares of the biotechnology company’s stock worth $995,000 after purchasing an additional 905 shares in the last quarter. Wasatch Advisors LP acquired a new position in shares of Repligen during the 1st quarter worth approximately $146,513,000. Louisiana State Employees Retirement System acquired a new position in shares of Repligen during the 1st quarter worth approximately $1,803,000. Krilogy Financial LLC lifted its position in shares of Repligen by 81.8% during the 1st quarter. Krilogy Financial LLC now owns 19,557 shares of the biotechnology company’s stock valued at $2,485,000 after buying an additional 8,801 shares in the last quarter. Finally, Generate Investment Management Ltd purchased a new position in shares of Repligen during the 1st quarter valued at approximately $4,892,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.